FOLR1-targeted actinium-225–based alpha-particle therapy eliminates ovarian cancer
Science Advances · 26.06.2026 · 12 (26)
DOI: 10.1126/sciadv.aef0121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 26.06.2026. Verfasst von Neetu Singh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Actinium, Alpha Particles, Folate Receptor 1. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institutes of Health, University of Utah, Sidney Kimmel Comprehensive Cancer Center.
Abstract (Originalsprache)
Despite the advancement in therapies, ovarian cancer treatment is challenging because of poor prognosis and high relapse associated with acquired resistance. Emerging targeted alpha particles, particularly actinium-225 ( 225 Ac), for treating refractory cancers have opened avenues for improved therapeutic options. Here, we describe a successful example of folate receptor 1 (FOLR1)–targeted 225 Ac alpha-particle therapy for treatment of ovarian cancer. Longitudinal positron emission tomography imaging demonstrated high tumor-specific uptake of αFOLR1 (anti-FOLR1 antibody) in SKOV3 xenografts. FOLR1-targeted 225 Ac demonstrated high therapeutic efficacy, achieving marked tumor regression, 80% survival, and 40% complete tumor elimination. The therapy resulted in tumor-specific double-stranded DNA damage, and no obvious toxicity was observed in normal tissues. Estimated human dosimetry showed high absorbed dose for tumor and minimal absorbed dose for healthy tissues, establishing its safety. In totality, FOLR1-targeted 225 Ac alpha-particle therapy is an efficacious and safe treatment with high feasibility for clinical translation to fight against ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT 84112, USA.
- Department of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, USA.
- Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
- Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
- Department of Civil and Environmental Engineering, University of Utah, Salt Lake City, UT 84112, USA.
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
ORCID-Profile: Neetu Singh, Esther Need, Lydia J Wilson, Firas Mourtada, Feng Guo, Tara Mastren, Taslim Al-Hilal, Anil K Sood, Scott C Miller, Shreya Goel, Sixiang Shi
Förderung
- National Institutes of Health
- University of Utah
- Sidney Kimmel Comprehensive Cancer Center
- 5 For the Fight Fellowship
Zitieren
APA
Singh, N., Need, E., Berndt, A., Goff, M., Wilson, L. J., Mourtada, F., Guo, F., Mastren, T., Al-Hilal, T., Sood, A. K., Maity, A., Miller, S. C., Minoshima, S., Goel, S., & Shi, S. (2026). FOLR1-targeted actinium-225–based alpha-particle therapy eliminates ovarian cancer. Science Advances, 12(26). https://doi.org/10.1126/sciadv.aef0121
Vancouver
Singh N, Need E, Berndt A, Goff M, Wilson LJ, Mourtada F, et al. FOLR1-targeted actinium-225–based alpha-particle therapy eliminates ovarian cancer. Science Advances. 2026;12(26). doi:10.1126/sciadv.aef0121
BibTeX
@article{Singh2026,
author = {Singh, Neetu and Need, Esther and Berndt, Ayden and Goff, Matthew and Wilson, Lydia J and Mourtada, Firas and Guo, Feng and Mastren, Tara and Al-Hilal, Taslim and Sood, Anil K and Maity, Amit and Miller, Scott C and Minoshima, Satoshi and Goel, Shreya and Shi, Sixiang},
title = {FOLR1-targeted actinium-225–based alpha-particle therapy eliminates ovarian cancer},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {26},
doi = {10.1126/sciadv.aef0121}
}
EUVIMED